Although EntreMed Inc. is now best known for developing anti-angiogenic molecules such as endostatin, the company did not actually begin life with the goal of commercializing that molecule, which sparked a huge run on the company's stock in May 1998, while it was still being tested in mice as an anti-tumor agent.
One of EntreMed's original goals was to enhance the oxygen-delivering capacity of red blood cells, via a method of causing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?